N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS

N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS

The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SCHNUTE Mark Edward, GERSTENBERGER Brian Stephen, SCHMITT Daniel Copley, UNWALLA Rayomand Jal, ROBINSON JR. Ralph Pelton, FLICK Andrew Christopher, MOUSSEAU James John, NUHANT Philippe Marcel, WU Huixian, KUNG Daniel Wei- Shung, THORARENSEN Atli, LOMBARDO Vincent Michael, TRUJILLO John Isidro
Format: Patent
Sprache:eng ; spa
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6. La presente invención se refiere a compuestos de dioxociclobutenilamino-3-hidroxi-picolinamida N-sustituida de las Fórmulas (IA y IB) (ver Fórmulas) Fórmula (IA) Fórmula (IB) o una sal o hidrato de aquellos aceptables desde el punto de vista farmacéutico, que inhiben el receptor de quimiocinas CC 6 (CCR6), a composiciones farmacéuticas que contienen estos compuestos, y al uso de estos compuestos para tratar o prevenir enfermedades, afecciones o trastornos que mejoran mediante inhibición de CCR6.